Table 2 Slope, intercept, Pearson correlation coefficient, and predicted LDL-C and non-HDL-C values based on simple linear regression of LDL-C or non-HDL-C on apoB at baseline (i.e., prior to receiving randomized treatment) and Week 12

Treatment Group

N^a

Slope

Intercept

apoB vs LDL-C

Pearson Correlation Coefficient (95 % CI) [R²]

Predicted^b

LDL-C Value (95 % CI) given apoB of 0.8 g/L

Predicted^b

LDL-C Value (95 % CI) given apoB of 0.9 g/L

 Pooled across treatment groups

721

2.04

0.36

0.72 (069, 0.76) [0.53]

1.98 (1.95, 2.01)

2.18 (2.16, 2.21)

 TG <2.26 mmol/L

602

2.35

0.13

0.77 (0.74, 0.80) [0.59]

2.01 (1.98, 2.04)

2.24 (2.22, 2.27)

 TG ≥2.26 mmol/L

119

2.35

−0.27

0.78 (0.70, 0.84) [0.61]

1.61 (1.50, 1.73)

1.85 (1.76, 1.93)

 ERN/LRPT

395

2.04

0.35

0.73 (0.68, 0.77) [0.53]

1.99 (1.94, 2.03)

2.19 (2.15, 2.23)

 TG <2.26 mmol/L

322

2.43

0.07

0.80 (0.75, 0.83) [0.64]

2.02 (1.98, 2.06)

2.26 (2.23, 2.30)

 TG ≥2.26 mmol/L

73

2.22

−0.16

0.74 (0.61, 0.83) [0.55]

1.63 (1.47, 1.79)

1.85 (1.73, 1.98)

 Placebo

326

1.99

0.38

0.72 (0.66, 0.76) [0.51]

1.98 (1.93, 2.02)

2.18 (2.14, 2.21)

 TG <2.26 mmol/L

280

2.20

0.23

0.72 (0.66, 0.78) [0.53]

2.00 (1.96, 2.04)

2.22 (2.18, 2.26)

 TG ≥2.26 mmol/L

46

2.51

−0.41

0.85 (0.73, 0.91) [0.72]

1.59 (1.43, 1.75)

1.84 (1.71, 1.97)

 ERN/LRPT

394

2.30

0.04

0.82 (0.79, 0.85) [0.68]

1.88 (1.84, 1.91)

2.11 (2.07, 2.15)

 TG <2.26 mmol/L

321

2.61

−0.16

0.84 (0.80, 0.87) [0.70]

1.93 (1.90, 1.97)

2.20 (2.15, 2.24)

 TG ≥2.26 mmol/L

73

1.99

0.13

0.86 (0.78, 0.91) [0.74]

1.73 (1.65, 1.81)

1.93 (1.86, 2.00)

 Placebo

323

2.09

0.27

0.73 (0.68, 0.78) [0.54]

1.94 (1.89, 1.98)

2.14 (2.07, 2.15)

 TG <2.26 mmol/L

279

2.35

0.06

0.77 (0.71, 0.81) [0.59]

1.94 (1.89, 1.98)

2.17 (2.13, 2.21)

 TG ≥2.26 mmol/L

44

1.68

0.50

0.69 (0.49, 0.82) [0.47]

1.84 (1.66, 2.02)

2.01 (1.86, 2.15)

Treatment Group

N^a

Slope

Intercept

apoB vs non-HDL-C

Pearson Correlation Coefficient (95 % CI) [R2]

Predicted^b

Non-HDL-C Value (95 % CI) given apoB of 0.8 g/L

Predicted^b

Non-HDL-C Value (95 % CI) given apoB of 0.9 g/L

 Pooled across treatment groups

721

2.97

0.21

0.87 (0.85, 0.89) [0.76]

2.59 (2.56, 2.62)

2.89 (2.87, 2.91)

 TG <2.26 mmol/L

602

2.82

0.31

0.84 (0.82, 0.87) [0.71]

2.57 (2.54, 2.60)

2.85 (2.83, 2.88)

 TG ≥2.26 mmol/L

119

2.59

0.81

0.85 (0.79, 0.89) [0.72]

2.88 (2.78, 2.98)

3.14 (3.06, 3.21)

 ERN/LRPT

395

2.95

0.25

0.87 (0.85, 0.89) [0.76]

2.61 (2.57, 2.65)

2.90 (2.87, 2.94)

 TG <2.26 mmol/L

322

2.82

0.32

0.86 (0.83, 0.89) [0.74]

2.58 (2.54, 2.61)

2.86 (2.83, 2.89)

 TG ≥2.26 mmol/L

73

2.38

1.07

0.81 (0.71, 0.87) [0.65]

2.97 (2.83, 3.10)

3.20 (3.10, 3.31)

 Placebo

326

3.00

0.17

0.87 (0.84, 0.89) [0.75]

2.57 (2.53, 2.61)

2.87(2.84, 2.90)

 TG <2.26 mmol/L

280

2.82

0.30

0.82 (0.78, 0.86) [0.67]

2.56 (2.52, 2.60)

2.84 (2.81, 2.88)

 TG ≥2.26 mmol/L

46

2.87

0.46

0.91 (0.83, 0.95) [0.82]

2.76 (2.62, 2.90)

3.05 (2.94, 3.15)

 ERN/LRPT

394

3.28

-0.13

0.89 (0.87, 0.91) [0.79]

2.49 (2.45, 2.53)

2.82 (2.78, 2.86)

 TG <2.26 mmol/L

321

3.15

-0.06

0.87 (0.84, 0.90) [0.76]

2.47 (2.43, 2.51)

2.78 (2.74, 2.83)

 TG ≥2.26 mmol/L

73

3.36

-0.12

0.88 (0.82, 0.92) [0.78]

2.56 (2.44, 2.68)

2.89 (2.78, 3.00)

 Placebo

323

3.21

-0.04

0.87 (0.84, 0.90) [0.76]

2.52 (2.48, 2.56)

2.84 (2.80, 2.88)

 TG <2.26 mmol/L

279

3.00

0.12

0.85 (0.82, 0.88) [0.73]

2.52 (2.48, 2.57)

2.82 (2.79, 2.86)

 TG ≥2.26 mmol/L

44

3.60

-0.33

0.89 (0.79, 0.93) [0.78]

2.55 (2.35, 2.75)

2.91 (2.75, 3.07)